ketorolac has been researched along with Neoplasm Metastasis in 6 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Preoperative, but not postoperative, administration of the nonsteroidal antiinflammatory drug ketorolac and/or resolvins, a family of specialized proresolving autacoid mediators, eliminated micrometastases in multiple tumor-resection models, resulting in long-term survival." | 3.91 | Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases. ( Bhasin, M; Bhasin, SS; Bielenberg, DR; Chang, J; Fishbein, A; Gartung, A; Gilligan, MM; Hammock, BD; Huang, S; Kieran, MW; Panigrahy, D; Piwowarski, J; Schmidt, BA; Serhan, CN; Soler-Ferran, D; Sparks, MA; Staffa, SJ; Sukhatme, V; Sukhatme, VP; Sulciner, ML; Yang, H; Yang, J, 2019) |
| "This retrospective analysis suggests that intraoperative administration of ketorolac decreases the risk of breast cancer relapse compared with other analgesícs." | 3.76 | Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. ( Berliere, M; De Kock, M; Forget, P; Legrand, C; Machiels, JP; Nussbaum, B; Vandenhende, J, 2010) |
| "morphine) were found to induce triple negative breast cancer (TNBC) metastasis while nonsteroidal anti-inflammatory drugs (i." | 1.56 | Postoperative administration of ketorolac averts morphine-induced angiogenesis and metastasis in triple-negative breast cancer. ( Cao, M; Cheng, S; Fu, G; Ji, F; Liu, Z; Wang, C, 2020) |
| "The intraoperative use of NSAIDs in breast cancer patients (Centre 1) is associated with a reduced recurrence rate (HR = 0." | 1.39 | Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. ( Berliere, M; Canon, JL; Coulie, PG; De Kock, M; Forget, P; Kremer, Y; Legrand, C; Machiels, JP; Poncelet, AJ; Stainier, A; Tombal, B, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Z | 1 |
| Cheng, S | 1 |
| Fu, G | 1 |
| Ji, F | 1 |
| Wang, C | 1 |
| Cao, M | 1 |
| Desmedt, C | 1 |
| Demicheli, R | 1 |
| Fornili, M | 1 |
| Bachir, I | 1 |
| Duca, M | 1 |
| Viglietti, G | 1 |
| Berlière, M | 3 |
| Piccart, M | 1 |
| Sotiriou, C | 1 |
| Sosnowski, M | 1 |
| Forget, P | 3 |
| Biganzoli, E | 1 |
| Panigrahy, D | 1 |
| Gartung, A | 1 |
| Yang, J | 1 |
| Yang, H | 1 |
| Gilligan, MM | 1 |
| Sulciner, ML | 1 |
| Bhasin, SS | 1 |
| Bielenberg, DR | 1 |
| Chang, J | 1 |
| Schmidt, BA | 1 |
| Piwowarski, J | 1 |
| Fishbein, A | 1 |
| Soler-Ferran, D | 1 |
| Sparks, MA | 1 |
| Staffa, SJ | 1 |
| Sukhatme, V | 1 |
| Hammock, BD | 1 |
| Kieran, MW | 1 |
| Huang, S | 1 |
| Bhasin, M | 1 |
| Serhan, CN | 1 |
| Sukhatme, VP | 1 |
| Machiels, JP | 2 |
| Coulie, PG | 1 |
| Poncelet, AJ | 1 |
| Tombal, B | 1 |
| Stainier, A | 1 |
| Legrand, C | 2 |
| Canon, JL | 1 |
| Kremer, Y | 1 |
| De Kock, M | 2 |
| Guo, Y | 1 |
| Kenney, SR | 1 |
| Muller, CY | 1 |
| Adams, S | 1 |
| Rutledge, T | 1 |
| Romero, E | 1 |
| Murray-Krezan, C | 1 |
| Prekeris, R | 1 |
| Sklar, LA | 1 |
| Hudson, LG | 1 |
| Wandinger-Ness, A | 1 |
| Vandenhende, J | 1 |
| Nussbaum, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Perioperative Ketorolac in High Risk Breast Cancer Patients With and Without Inflammation. A Prospective Randomized Placebo-controlled Trial.[NCT01806259] | Phase 3 | 203 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of death from any cause assessed up to 5 years) (NCT01806259)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketorolac 30 mg | 93 |
| NaCl 0.9% 3mL | 105 |
2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years) (NCT01806259)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketorolac 30 mg | 80 |
| NaCl 0.9% 3mL | 96 |
6 other studies available for ketorolac and Neoplasm Metastasis
| Article | Year |
|---|---|
Postoperative administration of ketorolac averts morphine-induced angiogenesis and metastasis in triple-negative breast cancer.
Topics: Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line, Tumor; Female; Huma | 2020 |
Potential Benefit of Intra-operative Administration of Ketorolac on Breast Cancer Recurrence According to the Patient's Body Mass Index.
Topics: Adult; Aged; Body Mass Index; Breast Neoplasms; Female; Humans; Intraoperative Care; Ketorolac; Midd | 2018 |
Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases.
Topics: Animals; Docosahexaenoic Acids; Immunity, Cellular; Ketorolac; Male; Mice; Mice, Knockout; Neoplasm | 2019 |
Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Carcinoma, Non-Small-Cell | 2013 |
R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis.
Topics: Allosteric Regulation; Aminoquinolines; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; cdc42 | 2015 |
Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis.
Topics: Adult; Aged; Analgesics; Analgesics, Opioid; Analysis of Variance; Anti-Inflammatory Agents, Non-Ste | 2010 |